Hepatitis C eradication: A long way to go

被引:13
作者
Waheed, Yasir [1 ]
机构
[1] Fdn Univ Islamabad, Fdn Univ Med Coll, Islamabad 46000, Pakistan
关键词
Hepatitis C virus; Treatment; Diagnostics; Screening; Transfusion; INCOME COUNTRIES; UNITED-STATES; VIRUS; BURDEN; STRATEGIES; INFECTION; PAKISTAN; DISEASE; ACCESS;
D O I
10.3748/wjg.v21.i43.12510
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis C virus (HCV) is a major global health problem with high morbidity and mortality. About 185 million people are living with HCV, of which 80% are living in low and middle income countries. With the development of new highly effective treatments for HCV, it is considered that the eradication of HCV may only be one step away. The major problem with new treatment options is its high price. The price of sofosbuvir-based treatment for one patient in the United States is US$85000-110000, while the actual production cost of a 12 wk direct-acting antiviral regimen is less than US$250. Another major hindrance in HCV eradication is the lack of quality management of blood transfusion screens. Due to the lack of HCV screening, 75% of people in the United States with HCV infection are unaware of their positive HCV status. The control of massive HCV pandemic will require a significant financial investment, political will, and support from medical, pharmaceutical, and civil organizations around the globe.
引用
收藏
页码:12510 / 12512
页数:3
相关论文
共 18 条
  • [1] [Anonymous], POL ER ENDG STRAT PL
  • [2] Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States
    Averhoff, Francisco M.
    Glass, Nancy
    Holtzman, Deborah
    [J]. CLINICAL INFECTIOUS DISEASES, 2012, 55 : S10 - S15
  • [3] Can hepatitis C be eradicated in the United States?
    Edlin, Brian R.
    Winkelstein, Emily R.
    [J]. ANTIVIRAL RESEARCH, 2014, 110 : 79 - 93
  • [4] Getchell JP, 2013, MMWR-MORBID MORTAL W, V62, P362
  • [5] A path to eradication of hepatitis C in low- and middle-income countries
    Graham, Camilla S.
    Swan, Tracy
    [J]. ANTIVIRAL RESEARCH, 2015, 119 : 89 - 96
  • [6] Hepatitis C, 2015, LANCET, V385, P1045, DOI [10.1016/S0140-6736(15)60584-0, DOI 10.1016/S0140-6736(15)60584-0]
  • [7] Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
    Hill, Andrew
    Khoo, Saye
    Fortunak, Joe
    Simmons, Bryony
    Ford, Nathan
    [J]. CLINICAL INFECTIOUS DISEASES, 2014, 58 (07) : 928 - 936
  • [8] Treating Hepatitis C in Lower-Income Countries
    Jayasekera, Channa R.
    Barry, Michele
    Roberts, Lewis R.
    Nguyen, Mindie H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) : 1869 - 1871
  • [9] Hepatitis C drug affordability
    Kamal-Yanni, Mohga
    [J]. LANCET GLOBAL HEALTH, 2015, 3 (02): : E73 - E74
  • [10] Current testing strategies for hepatitis C virus infection in blood donors and the way forward
    Marwaha, Neelam
    Sachdev, Suchet
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (11) : 2948 - 2954